Attached files

file filename
EX-31.2 - EX-31.2 - KERYX BIOPHARMACEUTICALS INCd116816dex312.htm
EX-31.1 - EX-31.1 - KERYX BIOPHARMACEUTICALS INCd116816dex311.htm
EX-32.1 - EX-32.1 - KERYX BIOPHARMACEUTICALS INCd116816dex321.htm
EX-21.1 - EX-21.1 - KERYX BIOPHARMACEUTICALS INCd116816dex211.htm
10-K - FORM 10-K - KERYX BIOPHARMACEUTICALS INCd116816d10k.htm
EX-32.2 - EX-32.2 - KERYX BIOPHARMACEUTICALS INCd116816dex322.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Keryx Biopharmaceuticals, Inc.:

We hereby consent to the incorporation by reference in the following registration statements of our reports dated February 26, 2016, with respect to the consolidated balance sheets of Keryx Biopharmaceuticals, Inc. (the “Company”) as of December 31, 2015 and 2014, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2015, and the effectiveness of Keryx Biopharmaceuticals, Inc. internal control over financial reporting, which appear in this annual report on Form 10-K of the Company for the year ended December 31, 2015:

 

    Form S-8 dated February 5, 2001 (File No. 333-55006)

 

    Form S-8 dated September 29, 2004 (File No. 333-119377)

 

    Form S-8 dated April 6, 2006, as amended (File No. 333-133052)

 

    Form S-8 dated July 31, 2007 (File No. 333-145003)

 

    Form S-8 dated March 25, 2010 (File No. 333-165710)

 

    Form S-8 dated August 2, 2013 (File No. 333-190358)

 

    Form S-3 dated August 2, 2013 (File No. 333-190353)

/s/ UHY LLP

New York, New York

February 26, 2016